Brief: Gubra Partner Boehringer Ingelheim Advances Treatment Of Obesity Into Mid-Stage Development
08/12/2025 07:12
Dec 8 (Reuters) - Gubra A/S GUBRA.CO: BOEHRINGER INGELHEIM ADVANCES NEXT GENERATION TRIPLE-AGONIST PEPTIDE FOR TREATMENT OF OBESITY INTO MID-STAGE DEVELOPMENT Source text: ID:nMFN8Kz4ZP Further company coverage: GUBRA.CO (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))